Odimma Therapeutics, a Strasbourg, France-based biotechnology company which specializes in personalized cancer immunotherapy, raised €2M in Seed funding.
Backers included Capital Grand Est, Alsace Business Angels, Angels Santé, and BpiFrance.
The company intends to use the funds to secure the preparation on its First-in-Man clinical trial with ODI-2001, an innovative first-in-class personalized immunotherapy against cancer.
In recent months, Odimma Therapeutics has completed the proof of activity experiments of its lead product ODI-2001 in several hard-to-treat preclinical cancer models. In parallel, the company has secured the pharmaceutical process for the production of ODI-2001. This relies on pharmaceutical partnerships with players in the field including myNEO (Ghent, Belgium) for neoepitope prediction by artificial intelligence, Touchlight Genetics (Hampton, UK) for the production of synthetic DNA and ABL Europe (Illkirch, France) for the production of the viral component of ODI-2001.
Odimma is led by Jean-Marc Limacher, M.D., Chairman.
FinSMEs
03/05/2023